PHATHOM PHARMACEUTICALS INC (PHAT)
US71722W1071 - Common Stock
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
The 3 Best Healthcare Stocks to Buy in May 2024
Healthcare firms can make large amounts of money, particularly in the U.S. Here are the three best healthcare stocks to buy now.
PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
PHAT stock results show that Phathom Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Phathom Pharmaceuticals (NASDAQ:PHAT) just reported results for the first quart...
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Over 17,500 total prescriptions for VOQUEZNA® products have been dispensed, launch-to-date, a 361% increase since last quarterly report Net revenues of...
Notable Thursday Option Activity: APPN, PHAT, PARA
Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
Commit To Buy Phathom Pharmaceuticals At $7.50, Earn 28.2% Annualized Using Options
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
/PRNewswire/ -- SynOx Therapeutics Limited ("SynOx" or the "Company"), the late-stage clinical biopharmaceutical company, is pleased to announce the close of a...
Commit To Buy Phathom Pharmaceuticals At $7.50, Earn 18.1% Annualized Using Options
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
FLORHAM PARK, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing...
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
National TV and digital media campaign aims to motivate millions of people suffering from Erosive GERD to learn more about VOQUEZNA® (vonoprazan), the first and only FDA-approved potassium-competitive acid blocker (PCAB)
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
National TV and digital media campaign aims to motivate millions of people suffering from Erosive GERD to learn more about VOQUEZNA® (vonoprazan), the...
PHAT Makes Bullish Cross Above Critical Moving Average
PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023
PHAT stock results show that Phathom Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Phathom Pharmaceuticals (NASDAQ:PHAT) just reported results for the fourth quar...
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Launched VOQUEZNA® (vonoprazan) tablets in November 2023 for the treatment of Erosive GERD (gastroesophageal reflux disease), achieving net revenues of...
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
Phathom Pharmaceuticals to host a conference call on Thursday, March 7, 2024, at 8:30 a.m. ET to report Q4 and full year 2023 financial results....
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Phathom management will participate in a fireside chat at the Guggenheim Biotechnology Conference on February 7, 2024, at 1:30 p.m. ET. ...
Phathom Pharmaceuticals says Takeda Pharmaceutical sold 3.7M shares (NASDAQ:PHAT)
Phathom Pharmaceuticals experiences insider selling as Akeba Pharmaceutical sells 3.7M shares.
Commit To Purchase Phathom Pharmaceuticals At $5, Earn 10.6% Annualized Using Options
'Top Pick for 2024': Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales
Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT),
Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
New drug application (NDA) seeks U.S. Food and Drug Administration (FDA) approval for VOQUEZNA® as a daily treatment for heartburn associated with...
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available at major retail pharmacies and through BlinkRx....
Phantom Pharmaceuticals files for $500M mixed securities shelf (NASDAQ:PHAT)
Phantom Pharmaceuticals (PHAT) plans to raise up to $500M through the sale of mixed securities, according to a recent filing.